Over the years, I have experienced many things as a healthcare consumer that have made me want to rip my hair out (or let out a visceral scream). As a journalist, too, many a…
Continue Reading
Clinical trials technology company Science 37 went public during the Covid-19 pandemic, a time when drug developers readily embraced technologies that enable patients to participate in drug studies from their homes. Decentralized clinical trials…
Continue Reading
Beneath the Californian sunshine (and a few showers) at JP Morgan, a revolution simmers. Not a political one, but a healthcare revolution propelled by necessity and fueled by innovation. Imagine a future where groundbreaking…
Continue Reading
News and social media are saturated with articles about the demand for and shortage of glucagon-like peptide-1 (GLP-1) drugs marketed for weight loss. The best-known of these drugs is semaglutide, sold under the brand…
Continue Reading
The excitement around artificial intelligence has been palpable for some time, dominating industry discussions and mobilizing capital for investment opportunities, but as of late, there’s been a change in the air. The optimism that…
Continue Reading
These numbers are astounding.
Between 1999 and 2021, nearly 645,000 people died of an opioid overdose. That’s in 22 years. Since the end of the Revolutionary War in 1783, the cumulative deaths from all American…
My phone chimed with a notification, signaling the availability of a new CT test result in my online health portal. “Multiple bilateral pulmonary nodules measuring up to 8mm. May represent metastatic disease.”
This was several…
From time to time, the FDA convenes an outside group of experts to weigh in on an experimental drug or medical device, or to offer insight on a scientific matter that raises questions. The…
Continue Reading
Season 3 of MedCity’s Pivot Podcast continues with a focus on how life sciences are being transformed. One area that has recently gone through major changes is the world of clinical trials as the…
Continue Reading
More than 1,300 oncology drugs are in the development pipeline, waiting to potentially embark on the long journey toward their commercial debut. This journey is usually an arduous one, made even more difficult by…
Continue Reading
